ObsEva SA (OBSV)
(Delayed Data from NSDQ)
$13.89 USD
-0.12 (-0.86%)
Updated May 3, 2019 04:13 PM ET
After-Market: $13.76 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[OBSV]
Reports for Purchase
Showing records 41 - 60 ( 170 total )
Industry: Medical - Biomedical and Genetics
Q3; Reduced PT Due to Adjustment to Our Linzagolix/UF U.S. Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Cash Replenished; Uterine Fibroid Data Favorable; Reducing PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Q2:20 Recap; MAA/NDA Filing, Commercial Partner On the Horizon
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Selloff Overdone; KOLs Enthusiastic About Linzagolix/UF Ph3 PRIMROSE Data
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
PRIMROSE Data Release Imminent; Nolasiban Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Nolasiban China Pre-IND Update; Key Catalyst Preview--UF Ph3 Readouts on July 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
New Potential Linzagolix Indication; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
1Q20 Financial Results Reported; PRIMROSE 1 Data Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Q1 Financials; Two Key Ph3 Data Readouts for UF Anticipated in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Perspectives on Endometriosis Outlook for Linzagolix; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Myovant Partnership Terms Bode Well for Linzagolix; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
EDELWEISS Shall Take Longer to Bloom; Reducing PT to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Linzagolix Ph3: COVID-19 Delays Endometriosis Trials, UF Data On-Track for Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
2019 Financials Reported; Multiple Catalysts Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Biomedical and Genetics
Emerging Pharma: Upcoming Material Catalysts in Companies with Plenty of Cash
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Q4/FY19; We Anticipate Positive Linzagolix/UF Phase 3 Catalysts in Q2:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
We See Attractive Upside for OBSV in 2020, With Anticipated Clinical Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L